Kornimate/medical-research-clean huggingface dataset:
prophylactic anti-arrhythmic therapy with amiodarone in critically ill patients admitted for an out-of-hospital cardiac arrest with initial shockable rhythm

Conditions: Ventricular Arrhythmias and Cardiac Arrest

Summary: to determine if prophylactic administration of amiodarone for 72 hours in critically ill patients admitted after an ohca with shockable rhythm, with a confirmed or a presumed cardiac cause, decreases the incidence of a composite endpoint of 30-day (starting from inclusion) all-cause mortality and/or severe in-hospital ventricular arrhythmia recurrence (ventricular fibrillation and/or ventricular tachycardia requiring intervention including re-arrest)


Eligibility criteria:
inclusion criteria: 1. patient aged ≥ 18 years 2. admitted in intensive care unit 3. out-of-hospital cardiac arrest with initial shockable rhythm 4. presumed cardiac or unknown cause 5. delay between rosc and screening for randomisation \< 6 hours 6. informed consent from the patient or a surrogate or deferred consent 7. affiliated to or benefiting from a social insurance exclusion criteria: 1. cardiac arrest secondary to an extra-cardiac cause (suspected or confirmed) 2. indication for amiodarone decided by the physician at icu admission 3. no central venous catheter available for continuous infusion of amidoarone 4. thyroid disease under treatment 5. history of cardiac conduction disorders, not treated by permanent pacemaker 6. any contra indication to amiodarone treatment 7. refractory ventricular arrhythmia or electrical storm 8. need for veno-arterial extracorporeal membrane oxygenation (va-ecmo) at admission 9. known limitations in therapy and do not resuscitate-order 10. moribund patient due to pre-arrest history (estimated life expectancy \< 3 months) 11. pregnant or breastfeeding women 12. patient needing a nadolol treatment due to qt long syndrome or catecholaminergic polymorphic ventricular tachycardia 13. patient with known pulmonary fibrosis 14. patient with known interstitial lung disease
resolution of thrombi in left atrial appendage with edoxaban

Conditions: Atrial Fibrillation; Left Atrial Appendage Thrombosis

Summary: non-valvular (nv) atrial fibrillation (af) increases the risk of stroke by approximately fivefold. the atrial thrombi associated with af are seen within the left atrial appendage (laa) in most cases (\> 90%). anticoagulation with a vitamin-k antagonist (vka) is recommended to prevent thromboembolic complications and to resolve thrombi. non-vka oral anticoagulants (noacs) have replaced the vka for the thromboprophylaxis in patients with nvaf since 2010. therefore, noac can be the excellent alternative to vka concerning resolving preexisting laa thrombi because of its rapid onset of action and no need of bridging with heparin. however, there is still lack of data regarding the optimal treatment for patients with af and thrombi in laa with noac. there are only several case reports of the efficacy of noacs in resolving laa thrombi available. edoxaban, which has data showing efficacy and safety in thromboprophylaxis, can be the new option for treatment of patients with af and laa thrombi. the purpose of this study is to evaluate the efficacy of edoxaban in resolving the laa thrombi, which is related with nonvalvular af.


Eligibility criteria:
inclusion criteria: * men or women aged ≥ 20 years * hemodynamically stable nonvalvular af or atrial flutter * laa thrombus documented by tee up to 72 hours prior to start of study medication * vka or noac-naïve or untreated within 1 month prior to sign the informed consent * vka pretreated but under the therapeutic international normalized ratio levels (\<2.0; documented with at least 2 consecutive measurements that are at least 24 hours apart) within last 6 weeks * women of childbearing potential and men must agree to use adequate contraception when sexually active exclusion criteria: * transient ischemic attack within 3 days prior to study inclusion * severe, disabling stroke (modified rankin score of 4-5, inclusive) within 3 months or any stroke within 14 days before the start of study drug * acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to study inclusion * acute myocardial infarction within the last 14 days prior to study inclusion * cardiac-related criteria: previous intracardiac thrombus, free-floating ball thrombus, intracardiac tumor, known left ventricular or aortic thrombus * active bleeding or high risk for bleeding contraindicating anticoagulant therapy
internet app to self-manage occasional low back pain

Conditions: Low Back Pain

Summary: nonspecific low back pain (nlbp) is the diagnosis for 85% of low back pain sufferers with no underlying medical cause (e.g., herniated disc, spinal stenosis) that requires physician care. treatment, however, is impractical for many physicians to implement during office visits, and there are relatively few providers for nlbp treatment that follow national pain control guidelines. this study evaluated the efficacy of an on-line intervention using desktop computers or mobile technology to help users self treat nlbp occurrences and to engage in activities to decrease future occurences.

methods. a total of 606 adults, 18 years of age and older were recruited, screened, and consented online. they were assessed on-line at baseline, at two months weeks, and at four months after the baseline assessments, participants were randomized into nlbp treatment (tx), alternative website control (awc), and no-contact control groups. the tx and awc groups received 8 weekly emails prompt to visit their respective experimental websites. add details here.

Eligibility criteria:
inclusion criteria: * suffered low back pain in previous 3 months * employed or family of employee exclusion criteria: * on-going medical care for low back pain * positive response to questions about symptoms which medically disqualify potential participant

Keywords: low back pain internet app prevention treatment
efficacy of amiloride and hypertonic saline in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this research study is to determine whether the combination of inhaled amiloride and a concentrated salt solution is better than the salt solution itself for cystic fibrosis (cf) patients. in cf, airway secretions are thick and dehydrated. many patients use inhaled salt solutions to help draw water into their secretions so that they are easier to get rid of with chest physiotherapy ("chest pt") and cough. unfortunately, these salt solutions are reabsorbed very quickly by the airways, so the beneficial effects may not last very long. in the hopes of prolonging their effects, the drug amiloride could be used in combination to slow salt and water reabsorption from airways. amiloride is a medication that has been given by mouth for high blood pressure for many years. it is possible that the combination of salt solutions and inhaled amiloride may significantly improve the clearance of secretions in cf, which would be expected to improve lung function in cf.


Eligibility criteria:
inclusion criteria: * established diagnosis of cf * 2 gene mutations identified, or * sweat chloride \> 60 mmol/l, and * 1 or more typical cf clinical features * age \> 14 years * able to perform spirometry and have post-bronchodilator fev1 \> 50% of predicted at screening * oxyhemoglobin saturation (by pulse oximetry) \> 92% on room air * able to provide informed consent exclusion criteria: * unstable lung disease: * fev1 \> 15% below best clinical measurement within 6 months * requirement for iv antibiotics within 4 weeks of screening * requirement for any change in pulmonary medication within 2 weeks of screening * evidence of reactive airways * clinical diagnosis of asthma -\> 15% increase in fev1 after bronchodilator at screening * hypertonic saline use within 2 weeks of screening * unwilling or unable to either continue or discontinue cyclical therapies (e.g. inhaled tobramycin) for the 2 weeks prior to screening and the entire study period * pregnancy, breast-feeding, or unwillingness to use barrier contraception during the entire study period * history of allergy or intolerance to amiloride, hypertonic saline, quinine, albuterol, or related compounds * renal insufficiency (creatinine \> 1.5 mg/dl) * hyperkalemia (k+ \> 5.0 meq/l) * investigational drug use within 30 days of screening * radiation exposure within the past year that would exceed federal regulations by participating in the study
neoadjuvant folfirinox or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer

Conditions: Borderline Resectable Pancreatic Cancer

Summary: the aim of this study is to clarify the efficacy and safety of neoadjuvant folfirinox and nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.


Eligibility criteria:
inclusion criteria: 1. borderline resectable pancreatic cancer (based on nccn guideline version 2.2015) 2. first treatment for pancreatic cancer 3. performance status 0 or 1 4. adequate one marrow function 5. adequate renal function 6. obtained informed consent exclusion criteria: 1. other active concomitant malignancies 2. other severe medical conditions; contraindication of folfirinox, paclitaxel and gemcitabine 3. pregnant women 4. no informed consent
study of t specific immune response against delta-cd20 peptide in hematological malignancies b

Conditions: Hematological Malignancies B

Summary: cancer-specific splice variants gain significant interest as they generate neo-antigens, that could be targeted by immune cells. cd20, a membrane antigen broadly expressed in mature b cell lymphomas, is subject to an alternative splicing named delta-cd20 leading to loss of membrane expression of the spliced isoform. the investigators group would now determine if it's possible, in patients with lymphoproliferative b, to detect the presence of a specific memory response to delta-cd20 peptides. if this memory response exists, it will confirm the interest of this antigen as a target for tumor immunotherapy.


Eligibility criteria:
inclusion criteria: * for all patient : •written informed consent * for cohort a : * patient with hematological malignancy of high grade phenotype b (non hodgkin's lymphoma diffuse large cell) or low grade (mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma or waldenstrom disease), regardless the initial extension stage. * histologically or cytologically and immunophenotypical confirmed * patient candidate to a second-line or more therapy * first-line treatment with rituximab * for cohort b : * absence of prior treatment with an anti-cd20 antibody * histologically or cytologically and immunophenotypical confirmed exclusion criteria: * for all patients : * patient with any medical or psychiatric condition or disease, * patient under guardianship, curatorship or under the protection of justice and pregnant women * for cohort a : * patient with chronic lymphocytic leukemia * patient with indolent lymphoma relapsed more than 1 year after treatment with rituximab * patient allogeneic hematopoietic cells * patient with linked lymphoproliferative syndrome with congenital immunosuppression (eg scid, xlp ...) or acquired (post-transplant lymphoma)
the care transitions intervention

Conditions: Continuity of Patient Care

Summary: this intervention tests whether encouraging older patients and their caregivers to assert a more active role in their care transitions could improve clinical outcomes. patients are supported by a nurse transition coach and specific tools, including a personal health record.

see above.

Eligibility criteria:
inclusion criteria: * to be eligible for this study, patients from the participating delivery system had to: 1) be age 65 years or older, 2) be admitted to one of the participating delivery system's contract hospitals during the study period for a non-psychiatrically-related condition, 3) be community-dwelling (i.e., not from a long-term care facility), 4) reside within a predefined geographic radius of the hospital (thereby making a home visit feasible), 5) have a working telephone, 6) be english-speaking, 7) show no documentation of dementia in the medical record, 8) have no plans to enter hospice, 9) not be participating in another research protocol, and 10) have documented in their medical record at least one of 11 diagnoses, including stroke, congestive heart failure, coronary artery disease, cardiac arrhythmias, chronic obstructive pulmonary disease, diabetes, spinal stenosis, hip fracture, peripheral vascular disease, deep venous thrombosis, or pulmonary embolism. exclusion criteria: * those who did not meet the inclusion criteria.

Keywords: care transitions geriatric care coordination self-management chronic illness patient-centered care
ovulation trigger with hcg compared to gnrh agonist in patients with repeated ivf failures

Conditions: Infertility

Summary: ovulation trigger is needed in in vitro fertilization (ivf) to get mature eggs. routinely, human chorionic gonadotropin (hcg) is used for that purpose given its similarity to the natural hormone that does this job in a natural cycle (luteinizing hormone, lh). in a natural cycle another hormone takes part in the process (follicle stimulating hormone, fsh). to induce a natural-like ovulation surge that includes lh and fsh , gonadotropin releasing hormone (gnrh) agonist can be given. the purpose of this study is to find out which approach may work better in ivf patients who experienced 4 ivf failures.


Eligibility criteria:
inclusion criteria: * ivf patients with at least 4 consecutive failures. * on trigger day, no more than 10 follicles of 12 mm and up exclusion criteria: * history of moderate or severe ohss.
ryme medical tld pilot study

Conditions: Chronic Obstructive Pulmonary Disease

Summary: targeted lung denervation (tld) with the ryme medical lung denervation system in patients with chronic obstructive pulmonary disease (copd) - ryme medical tld pilot study

the study is a prospective, multi-center, non-randomized study to evaluate the safety and performance of the ryme medical lung denervation system in patients with chronic obstructive pulmonary disease (copd)

Eligibility criteria:
key inclusion criteria: * symptomatic chronic obstructive pulmonary disease * ≥40 years of age * smoking history of at least 10 pack years * candidate for bronchoscopy in the opinion of the investigator key exclusion criteria: * recent copd exacerbation or respiratory infection * prior lung intervention with device in place * pulmonary nodule or malignancy requiring treatment * current chemotherapy or radiation therapy and/or has received treatment within 6 months * current smoker, using e-cigarettes or vaping, or taking any inhaled substances not prescribed by a physician * clinically significant serious or unstable medical conditions (e.g., heart disease requiring treatment, uncontrolled diabetes) * pregnant, nursing, or intent to become pregnant during study duration

Keywords: copd dyspnea lung denervation bronchoscopic intervention lung disease lung diseases, obstructive respiratory tract diseases
sensory processing skills in toddler with joint hypermobility

Conditions: Child Development; Sensory Disorder; Hypermobility, Joint

Summary: shows that children and adults with joint hypermobility may be identified with common clinical problems that are unrelated, such as chronic fatigue, anxiety, and a range of gastrointestinal functional disorders \[4-6\]. considering the relationship of joint hypermobility with joint muscle tone and posture, sensory processing skills may also be affected in individuals with hypermobility. no study in the literature examines the relationship between joint hypermobility and sensory processing. this study was planned to detect joint hypermobility as early as 12-14 months and to examine its relationship with sensory processing skills.


Eligibility criteria:
inclusion criteria: 12-14 month old healthy children - exclusion criteria: * they had major congenital malformations, had genetic or chromosomal abnormalities, had known metabolic disorders, or had seizures.
carbon monoxide monitor for the measurement of end-tidal carbon monoxide levels in children with or without hemolysis

Conditions: Sickle Cell Anemia

Summary: people who have sickle cell anemia (hbss) produce red blood cells with shorter lifespans. these red blood cells breakdown faster, and this is called hemolysis. when red blood cells breakdown, a tiny amount of carbon monoxide (co) is released into the blood and is eliminated in exhaled breath. this research study will use a device called cosense™, which will measure carbon monoxide (co) levels in breath. the purpose of the study is to see how well the device measures the co levels that an individual breathes out.

subjects diagnosed with homozygous sickle cell anemia (hb ss) have red blood cells with a decreased lifespan, which leads to an increase in the rate of heme turnover. carbon monoxide (co) is a by-product of heme oxidation and is excreted in exhaled breath. the concentration of co in end-tidal breath can be measured and used to indicate the rate of heme oxidation, bilirubin production and the presence of hemolysis. the objective of this study is to characterize the performance of cosense™ in children with or without sickle cell anemia. this is a single-center, open-label, non-randomized, proof of concept study to characterize the ability of cosense™ to assess etco levels in subjects with a diagnosis of sickle cell anemia (hb ss). up to 40 children (5-14 years old), of which 20 participants will have a diagnosis of hb ss, will be enrolled. each participant will have two breath samples collected non-invasively, one immediately after the other. it takes approximately 120 seconds to collect the each breath sample. this study and investigational device are a non-significant risk to the patient. the nasal cannula is made of a biocompatibility-tested polyvinyl chloride (pvc) material with a soft open-end, and will be gently placed adjacent to one of the nostrils and partially inserted by approximately 5 mm. the objective of this study will be assessed through reproducibility of etco measurements and comparison of etco levels between children diagnosed with hb ss and healthy children. the study would help in the development of a portable co measurement device which has potential health applications in monitoring diseases with altered bilirubin metabolism.

Eligibility criteria:
inclusion criteria: * parental / legal guardian consent * subject assent for participants ages 7 and above * male and female children ages 5 - 14 years old * for hb ss subjects, hemoglobin ≤ 10 g/dl (based on a laboratory tests performed over the last 6 months and confirmed within 4 weeks prior to breath collection, as part of the subject's clinical care) exclusion criteria: * for healthy subjects, known to have the sickle cell trait * had a red blood cell transfusion within 12 weeks prior to enrollment * currently a primary smoker or was a primary smoker within 4 weeks prior to enrollment * exposed to second hand smoke within 24 hours prior to breath sample collections * have an upper respiratory infection within 2 weeks of etco measurements
study of nitazoxanide, peginterferon alfa-2a and ribavirin for the treatment of hepatitis c

Conditions: Chronic Hepatitis C

Summary: the purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis c in patients that have previously failed to respond to treatment with peginterferon and ribavirin.


Eligibility criteria:
inclusion criteria: * chronic hepatitis c genotype 1. * failed to respond to ≥12 weeks of peginterferon and ribavirin (\<2 log10 drop in hepatitis c virus ribonucleic acid (hcv rna) at week 12 or detectable hepatitis c virus ribonucleic acid (hcv rna) at week 24). exclusion criteria: * females of child-bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active. * males whose female partners are either pregnant or of child-bearing potential or not using birth control and are sexually active. * other causes of liver disease including autoimmune hepatitis. * transplant recipients receiving immune suppression therapy. * screening tests positive for anti-hepatitis a virus immunoglobulin m antibody (anti-hav igm ab), hepatitis b's antigen (hbsag), anti-hepatitis b core antigen immunoglobulin m antibody (anti-hbc igm ab) or anti-human immunodeficiency virus antibody (anti-hiv ab). * decompensated cirrhosis, history of variceal bleeding, ascites, hepatic encephalopathy, child-turcotte-pugh (ctp) score \>6 or model for end-stage liver disease (meld) score \>8. * alcohol consumption of \>40 grams per day or an alcohol use pattern that will interfere with the study. * absolute neutrophil count \<1500 cells/mm3; platelet count \<135,000 cells/mm3; hemoglobin \<12 g/dl for women and \<13 g/dl for men; or serum creatinine concentration ≥1.5 times upper limit of normal (uln). * hypothyroidism or hyperthyroidism not effectively treated with medication. * hemoglobin a1c (hgba1c) \>7.5 or history of diabetes mellitus. * body mass index (bmi) \>28. * history or other clinical evidence of significant or unstable cardiac disease. * history or other clinical evidence of chronic pulmonary disease associated with functional impairment. * serious or severe bacterial infection(s). * ulcerative or hemorrhagic/ischemic colitis. * pancreatitis. * history of severe or uncontrolled psychiatric disease, including severe depression, history of suicidal ideation, suicidal attempts or psychosis requiring medication and/or hospitalization. * history of uncontrolled severe seizure disorder. * requires concomitant theophylline or methadone. * history of immunologically mediated disease requiring more than intermittent anti-inflammatory medications for management or that requires frequent or prolonged use of corticosteroids. * history or other evidence of severe retinopathy or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension. * hemoglobinopathies. * history of hypersensitivity or intolerance to nitazoxanide or any of the excipients comprising the nitazoxanide tablets, peginterferon alfa-2a injectable solution or ribavirin tablets.

Keywords: hepatitis c, chronic
the impact of pituitary-thyroid and pituitary-adrenal axes function on covid-19 clinical course.

Conditions: COVID-19; Low Triiodothyronine Syndrome; Adrenal Insufficiency; Subacute Thyroiditis; Hypothyroidism; Hyperthyroidism

Summary: the main focus of the study is the assessment of hormonal function in the course of covid-19 infection with special regard for trends predicting clinical events defined as primary endpoints of the study.


Eligibility criteria:
inclusion criteria: * pcr-confirmed covid-19 infection * volunteers consenting to participate exclusion criteria: * no consent

Keywords: covid-19, thyroid, adrenal gland, pituitary, glucocorticoids